Lv1
44 积分 2024-06-17 加入
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
1个月前
已完结
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
1个月前
已完结
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes
2个月前
已完结
Potential eye disorders in people with and without Type 2 diabetes mellitus exposed to GLP-1 receptor agonists; an examination of the FAERS (FDA Adverse Event reporting System) database
3个月前
已完结
Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial
4个月前
已完结
The relationship between obesity and chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
5个月前
已完结
Mechanisms of diabetic kidney disease and established and emerging treatments
5个月前
已完结
The Epidemiology of Obesity
8个月前
已完结
Wilson Confidence Intervals for Binomial Proportions With Multiple Imputation for Missing Data
8个月前
已完结
Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment
9个月前
已完结
皖公网安备34019202002308
